Julia G. Butchko

Chief Development & Technology Officer, Immunovant at Roivant Sciences

Julia G. Butchko, Ph.D. has served as the Chief Development and Technology Officer of Immunovant, Inc. since November 2019. Prior to joining Immunovant, Dr. Butchko oversaw strategy and operations as Chief of Staff for the $4 billion Immunology and Neuroscience businesses at Lilly. She previously served as Vice President of Lilly’s Oncology Project Management and Clinical Development teams where she was responsible for over 100 global clinical trials, including immuno-oncology collaborations with Merck, Bristol-Myers Squibb, and AstraZeneca. Earlier in her career, Dr. Butchko held significant roles in product development, marketing, manufacturing, and quality.